Subscribe

Mainz Biomed N.V. (QUCY)

USD1.22 -0.05 (-3.57%)
DE NASDAQ Healthcare Medical - Diagnostics & Research
Address Robert Koch Strasse 50 55129
Mainz, DE
CEO Guido Baechler
Website mainzbiomed.com
IPO 2021-11-05
CIK 1874252 ISIN NL0015000LC2

Explore sections of this company profile

Also trades on NASDAQ Capital Market · MYNZ (USD) NASDAQ Global Market · QUCY (USD)
Description

Mainz Biomed N.V. is a specialized enterprise in the field of molecular genetics, primarily focused on cancer diagnostics. The company's core mission involves developing and producing market-ready molecular genetic diagnostic solutions specifically engineered for life-threatening medical conditions. Beyond creation, it actively engages in the global commercialization of its product portfolio, reaching markets across Europe, the United States, and other international territories. This firm was established on March 8, 2021, and maintains its headquarters in Mainz, Germany.

News Sentiment (7d)
44 Neutral

4 articles

Market Cap & Enterprise Value
Merger & Acquisition History

No mergers or acquisitions recorded for this company.

Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary Loading…
Indicator 1D1W2W3W1M
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
Averages
Trend
Price
Levels
Draw
USD1.22 -0.05 (-3.57%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
909.8K
Beta
2.23
Float Shares
3.55M
Free Float %
28.3%
Price Performance
1D5D1M3M6M YTD1Y3Y5Y10YMax
-22.58% +34.47% +424.64% +305.68% +219.38% +219.38% +219.38% +219.38% +219.38% +219.38% +219.38%
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
vs.
Loading histogram data…

Revenue flow

Revenue by geography

Revenue by segment

From To

Revenue composition

From To

By product

By geography

Financial Statements

Income Statement

Balance Sheet

Cash Flow Statement

Key Metrics

Financial Ratios

Employees

Financial Growth (CAGR)

Market Data

Price Targets & DCF
Current price
1.22
Ratings Trend (MoM) 0% Bullish
Rating 2026-05 Change
Strong Buy 0 0
Buy 0 0
Hold 1 0
Sell 0 0
Strong Sell 0 0
Quality scores
Composite Rating
C
Overall Score
2 / 5
Medium
DCF Score
1 / 5
Low
ROE Score
1 / 5
Low
ROA Score
1 / 5
Low
D/E Score
3 / 5
Medium
P/E Score
1 / 5
Low
P/Book Score
4 / 5
High
Operational MOAT
✗ Below peers
  • ✗
    Revenue growth Medical - Diagnostics & Research: +7.9%
    -39.9%
  • ✗
    EPS growth Medical - Diagnostics & Research: +30.8%
    +87.9% ★
  • ✗
    FCF margin FCF growth · Medical - Diagnostics & Research: +32.2%
    -3,322.6%
  • ✗
    EBIT margin Medical - Diagnostics & Research: +9.6%
    -2,948.8%
  • ✗
    ROIC Medical - Diagnostics & Research: +5.2%
    -681.5% Q1'26: -3,705.4%
  • ✗
    Share dilution Medical - Diagnostics & Research: 0.0%
    +519.4%
  • ✗
    Debt / EBITDA Net debt/EBITDA · Medical - Diagnostics & Research: -0.13×
    -0.17× Q1'26: -0.01×
Valuation Multiples From To
Price Forecast (3Y) From To
Model
Adjust
P/E
Theoretical Return — If Invested Today

* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.

DCF Interactive Model (UFCF)
Projection years:
Market assumptions
▶ WACC components (optional)
Ke (Cost of Equity) = Rf + β (0.43) × ERP
WACC = 86% × Ke + 14% × Kd (14.5%) × (1−t)

Modifying these values recalculates WACC automatically.

Business assumptions
—
Current price: 1.22
Enterprise Value: — Equity Value: — Terminal Value: — TV as % of EV: —

Base values reflect the latest available data for this company and market conditions.

Consensus Estimates
Metric Dec 2024
actual 		Dec 2025
actual 		Dec 2026
1 Rev. Ana.
1 EPS Ana. 		Dec 2027
1 Rev. Ana.
1 EPS Ana. 		Dec 2028
1 Rev. Ana.
1 EPS Ana. 		Dec 2029
1 Rev. Ana.
1 EPS Ana. 		Dec 2030
1 Rev. Ana.
1 EPS Ana.
Revenue
894.0K
est: 1.05M (-15.0%)
537.1K
est: 874.0K (-38.6%)
917.7K
917.7K – 917.7K
+5.0% YoY
2.49M
2.49M – 2.49M
+171.5% YoY
30.16M
30.16M – 30.16M
+1,110.4% YoY
74.02M
74.02M – 74.02M
+145.4% YoY
2.70M
2.70M – 2.70M
-96.4% YoY
EBITDA
-19.56M
est: -1.05M (-1,759.2%)
-15.22M
est: -874.0K (-1,641.5%)
-917.7K
-917.7K – -917.7K
-5.0% YoY
-2.49M
-2.49M – -2.49M
-171.5% YoY
-30.16M
-30.16M – -30.16M
-1,110.4% YoY
-74.02M
-74.02M – -74.02M
-145.4% YoY
-2.70M
-2.70M – -2.70M
+96.4% YoY
EBIT
-20.58M
est: -1.05M (-1,855.8%)
-15.84M
est: -874.0K (-1,712.0%)
-917.7K
-917.7K – -917.7K
-5.0% YoY
-2.49M
-2.49M – -2.49M
-171.5% YoY
-30.16M
-30.16M – -30.16M
-1,110.4% YoY
-74.02M
-74.02M – -74.02M
-145.4% YoY
-2.70M
-2.70M – -2.70M
+96.4% YoY
Net Income
-21.65M
est: -10.50M (-106.3%)
-16.21M
est: -2.77M (-485.4%)
-29.0K
-29.0K – -29.0K
+99.0% YoY
-29.0K
-29.0K – -29.0K
+0.0% YoY
-29.0K
-29.0K – -29.0K
+0.0% YoY
-38.7K
-38.7K – -38.7K
-33.3% YoY
-38.7K
-38.7K – -38.7K
+0.0% YoY
SGA
12.77M
est: 23.74M (-46.2%)
8.88M
est: 19.72M (-55.0%)
20.71M
20.71M – 20.71M
+5.0% YoY
56.23M
56.23M – 56.23M
+171.5% YoY
680.57M
680.57M – 680.57M
+1,110.4% YoY
1.67B
1.67B – 1.67B
+145.4% YoY
60.85M
60.85M – 60.85M
-96.4% YoY
EPS
-22.36
est: -10.84 (-106.3%)
-2.70
est: -2.86 (+5.6%)
-0.03
-0.03 – -0.03
+99.0% YoY
-0.03
-0.03 – -0.03
+0.0% YoY
-0.03
-0.03 – -0.03
+0.0% YoY
-0.04
-0.04 – -0.04
-33.3% YoY
-0.04
-0.04 – -0.04
+0.0% YoY
Historical Ratings (3M)
Date Rating Overall DCF ROE ROA D/E P/E P/B
2026-05-15 D+ 1/5 1/5 1/5 1/5 1/5 1/5 1/5
2026-05-14 D+ 1/5 1/5 1/5 1/5 1/5 1/5 1/5
2026-05-13 D+ 1/5 1/5 1/5 1/5 1/5 1/5 1/5
2026-05-12 D+ 1/5 1/5 1/5 1/5 1/5 1/5 1/5
2026-05-11 D+ 1/5 1/5 1/5 1/5 1/5 1/5 1/5
2026-05-08 D+ 1/5 1/5 1/5 1/5 1/5 1/5 1/5
2026-05-07 D+ 1/5 1/5 1/5 1/5 1/5 1/5 1/5
2026-05-06 D+ 1/5 1/5 1/5 1/5 1/5 1/5 1/5
2026-05-05 D+ 1/5 1/5 1/5 1/5 1/5 1/5 1/5
2026-05-04 D+ 1/5 1/5 1/5 1/5 1/5 1/5 1/5
2026-05-01 D+ 1/5 1/5 1/5 1/5 1/5 1/5 1/5
2026-04-30 D+ 1/5 1/5 1/5 1/5 1/5 1/5 1/5
2026-04-29 D+ 1/5 1/5 1/5 1/5 1/5 1/5 1/5
2026-04-28 D+ 1/5 1/5 1/5 1/5 1/5 1/5 1/5
2026-04-27 D+ 1/5 1/5 1/5 1/5 1/5 1/5 1/5
2026-04-24 D+ 1/5 1/5 1/5 1/5 1/5 1/5 1/5
2026-04-23 D+ 1/5 1/5 1/5 1/5 1/5 1/5 1/5
2026-04-22 D+ 1/5 1/5 1/5 1/5 1/5 1/5 1/5
2026-04-21 D+ 1/5 1/5 1/5 1/5 1/5 1/5 1/5
2026-04-20 D+ 1/5 1/5 1/5 1/5 1/5 1/5 1/5
2026-04-17 D+ 1/5 1/5 1/5 1/5 1/5 1/5 1/5
2026-04-16 D+ 1/5 1/5 1/5 1/5 1/5 1/5 1/5

Owner Earnings

Owner's Earnings (history)

Owner's Earnings history not available.

Owner alignment
Owner's Earnings TTM
—
OE per share TTM
—
Owner's Yield
—
Maintenance CapEx ratio
—
Maint CapEx / Avg PPE
—

Ownership Overview

Ownership breakdown

Ownership breakdown not available.

At a glance
Institutional holders
—
Total invested
—
Insider transactions (90d)
2
Beneficial owners (>5%)
0
Beneficial owners (>5%)

No beneficial ownership filings recorded.

Institutional Activity (13F)

Institutional ownership trend

Institutional history not available.

Top institutional holders

Top holders not available.

ETF Ownership

Top ETFs holding this stock

This company is not held by any ETF in our universe.

Insider Activity

Insider Activity — Latest Quarter

No insider activity available.

Insider buys vs sells (history)

Insider history not available.

Recent insider transactions From To
Date Person Role Transaction A/D Security Shares Price Value Owned after D/I Filing
2026-04-22 NATAN DAVID Director — — Ordinary Shares 0 0.00 — 0 D ↗
2026-04-22 Ben-Tzvi Avraham Director — — Ordinary Shares 0 0.00 — 2,000 D ↗

Executive team

Top executives
EBIT / Employee
-6.1K
Shares Outstanding
12.52M

Executive compensation

Executive compensation (annual)

Executive compensation not available.

CEO compensation breakdown

No CEO compensation history available.

Proxy statements

Proxy statements (DEF 14A)

No proxy statements available for this company yet.

Recent SEC filings

Recent SEC filings

No SEC filings available for this company yet.

Executive team

NameTitleCompensationGender
Guido Baechler CEO & Executive Director 315.4K male
William J. Caragol CFO & Senior VP 218.8K male
Christopher Von Toerne Chief Operating Officer — —
Stefan Erlach Head of Human Resources — male
ESG Score History

No data available for this company.

Senate Trading Activity

No Senate trading activity found for this company.

House Trading Activity

No House trading activity found for this company.

Market share among peers
Peer comparison — filtered group (TTM)
Your opinion

Share your view on this stock and instantly see how the community has voted over the last 6 months.

These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.

Dividend history

Earnings history

Earnings reports

Stock splits

Related companies

Largest companies in Medical - Diagnostics & Research